Samer Choucair, investment entrepreneur, affirmed that the recent developments in the global GLP-1 drug market represent an important turning point for the healthcare and pharmaceutical industries sector, noting that Saudi Arabia possesses the fundamentals needed to benefit from this accelerating growth and turn it into strategic investment opportunities supporting Vision 2030’s targets.
Choucair’s remarks came following the US Medicare program’s announcement of cutting the cost of GLP-1 drugs used in treating obesity and diabetes, including Wegovy, to roughly 50 dollars monthly for millions of beneficiaries, a step that will expand the user base for these treatments and strengthen demand rates for them in the coming years.
He explained that this development’s impact isn’t limited to the US market alone, but carries important global implications reflecting the growing trend toward expanding access to innovative treatments, which will lead to additional growth in global demand for this drug category.
Choucair said: “Cutting costs globally will make these treatments more attractive in Saudi Arabia and the region, creating investment opportunities in the Gulf that can’t be ignored. We’re looking at an important shift in the healthcare sector that could reflect on pharmaceutical manufacturing, health services, and medical technologies tied to these treatments.”
A Market Headed Toward $180 Billion
He noted that the GLP-1 drug market is experiencing exceptional growth globally, with projections pointing to its size reaching roughly 82 billion dollars during 2026, with the possibility of surpassing 180 billion dollars by 2035, driven by rising obesity and diabetes rates, increasing health awareness, and the expanding use of these treatments in many markets.
He affirmed that the Gulf states, led by Saudi Arabia, will be among the most prominent beneficiaries of this global growth, given rising local demand for treatment solutions tied to obesity and diabetes, alongside the continued expansion of health infrastructure and insurance coverage.
He explained that the Kingdom enjoys a strong, sustainable demand base, amid projections pointing to rising obesity rates among adults, in addition to the continued widespread prevalence of diabetes, making the Saudi market one of the largest promising regional markets in modern treatments tied to chronic diseases.
Vision 2030’s Pharmaceutical Localization Drive
He noted that Vision 2030 represents a pivotal factor in turning this growing demand into economic and investment opportunities, particularly with government focus on localizing pharmaceutical industries and strengthening local self-sufficiency in health products and advanced therapeutic technologies, saying: “The opportunity is now available to invest in Saudi Arabia in advanced pharmaceutical manufacturing and technology transfer. Partnerships with global players will accelerate the achievement of localization goals and strengthen the Kingdom’s position as a regional hub for advanced pharmaceutical industries.”
He added that Vision 2030’s targets aimed at raising the localization rate of the pharmaceutical industry represent an important opportunity for local and international investors to enter biomanufacturing projects and modern pharmaceutical technologies, particularly amid continued massive government investment in developing the healthcare sector and raising its efficiency.
He affirmed that the launch of Lifera, a Public Investment Fund subsidiary, reflects the Kingdom’s strategic direction toward building an integrated pharmaceutical ecosystem based on local manufacturing and the transfer of knowledge and advanced technologies, strengthening pharmaceutical security and creating new economic opportunities.
Where the Opportunities Lie
He noted that investment opportunities aren’t limited to pharmaceutical manufacturing alone, but extend to many supporting sectors, including specialized clinics, digital health services, and smart applications tied to chronic disease management and improving quality of life.
He added: “With the focus on quality of life in Vision 2030, GLP-1 treatments can be integrated with prevention and awareness programs and digital health applications, creating an integrated investment ecosystem encompassing specialized clinics, supporting services, and modern technologies.”
A Long-Term Investment Lens
Regarding investment strategies in the period ahead, Choucair affirmed the importance of focusing on long-term investments in the healthcare sector, explaining that companies operating in pharmaceuticals, health services, and biotechnology are poised to directly benefit from the expected growth in demand for these treatments, saying: “The healthcare sector in Saudi capital markets is seeing growing interest. Companies tied to pharmaceuticals, health services, and biotechnology will directly benefit from these trends. Diversifying between manufacturing and services reduces risk and ensures sustainable returns for investors.”
He stressed the importance of strategic partnerships and technology transfer as among the most important future growth drivers, adding: “Investing in technology transfer or contract manufacturing for this drug category represents a golden opportunity for Saudi and Gulf entrepreneurs seeking high-growth, sustainable sectors.”
He concluded his remarks by affirming that the convergence of the global trend toward expanding GLP-1 drug use with Vision 2030’s strategic goals creates a promising investment environment in the Kingdom, calling on investors to study available opportunities and prepare to benefit from the shifts underway in the healthcare sector.
Samer Choucair concluded the statement by saying: “Combining the global trend of lowering GLP-1 drug costs with the Kingdom’s strategic vision creates an ideal environment for smart investments in the health sector. Investors should move quickly to benefit from this historic opportunity that combines growth, innovation, and sustainability.”